ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bankrupt Orexigen to sell for $75 million

by Ryan Cross
April 29, 2018 | APPEARED IN VOLUME 96, ISSUE 18

Orexigen has struck a deal to sell itself for $75 million to a newly formed company called Nalpropion Pharmaceuticals. San Diego-based Orexigen filed for bankruptcy in March. Its main product is a weight loss pill called Contrave that didn’t sell as expected. Nalpropion was formed by an investor group including Pernix Therapeutics.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment